A Study of Patients Undergoing Surgical Treatment for Oesophageal Atresia

NCT ID: NCT06286826

Last Updated: 2024-03-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-12

Study Completion Date

2026-01-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oesophageal atresia (EA) is a rare congenital anomaly whose prevalence varies between 1 and 2 per 5000 live births in Europe. This condition is characterised by an interruption of the oesophagus often associated with the presence of a tracheo-oesophageal fistula (FTE).

Although considerable progress has been made in the treatment of AE in recent years, the aetiology of this defect is still not fully understood and several theories have been put forward to explain this phenomenon. What they have in common is an abnormal separation of the primary oesophagus and trachea. The main goal of AE treatment is the closure of the FTE using surgical techniques.

This is a non-profit, multicentre longitudinal observational cohort study. This study will enrol patients who underwent surgery for oesophageal atresia during the period 2011-2021 and are still in follow-up at participating clinical centres.

The primary objective is to assess the incidence of musculoskeletal abnormalities, of any type, in the long term (4 years after surgery) in patients with oesophageal atresia treated surgically by two different approaches: postero-lateral thoracotomy and mini-thoracotomy with muscle preservation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atresia Esophagus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with oesophageal atresia minithoracotomy

Patients with oesophageal atresia who underwent a minithoracotomy between 2011-2021

Minithoracotomy

Intervention Type PROCEDURE

Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)

Patients with oesophageal atresia postero-lateral thoracotomy

Patients with oesophageal atresia who underwent a postero-lateral thoracotomy between 2011-2021

Postero-lateral thoracotomy

Intervention Type PROCEDURE

this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Postero-lateral thoracotomy

this incision extends from the anterior axillary line, goes posteriorly behind the scapula and includes the division of the fibres of the latissimus dorsi muscle and the serratus anterior muscle. The latter approach presents the risk of numerous long-term musculoskeletal complications such as costal abnormalities (costal hypoplasia, costal fusion), winged scapula, scoliotic spine posture

Intervention Type PROCEDURE

Minithoracotomy

Minithoracotomy aims to preserve the muscles of the rib cage by retracting or disconnecting them rather than sectioning them (muscle sparing technique)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with oesophageal atresia (type III according to Ladd's classification);
* Patients who underwent their first operation for oesophageal atresia in the period 2011-2021
* Signature of written informed consent and consent to the study and privacy.

Exclusion Criteria

* Not signature of written informed consent and consent to the study and privacy.
Minimum Eligible Age

1 Day

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meyer Children's Hospital IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Elisa Severi

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elisa Severi

Role: PRINCIPAL_INVESTIGATOR

Meyer Children's Hospital IRCCS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Spedali Civili di Brescia

Brescia, , Italy

Site Status RECRUITING

Meyer Children's Hospital IRCCS

Florence, , Italy

Site Status RECRUITING

Ospedale Bambino Gesù di Roma

Roma, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elisa Sieri

Role: CONTACT

055 5662900

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Daniele Alberti

Role: primary

Elisa Severi

Role: primary

0555662900

Andrea Conforti, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ATRESO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.